Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, Coherus BioSciences, Gyros Protein Technologies AB, Fresenius Kabi, Viatris, Amgen Inc.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Psoriasis Biosimilars Market - (By Drug Class (TNF-alpha inhibitors (Infliximab, Etanercept, Adalimumab), Other biosimilars), By Route of Administration (Subcutaneous, Intravenous, Oral, Topical), By Indication (Plaque psoriasis, Psoriatic arthritis, Other types), By Distribution Channel (Hospital pharmacies, Retail pharmacy chains, Online pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Psoriasis Biosimilars Market is valued at US$ 8.5 billion in 2023, and it is expected to reach US$ 19.3 billion by 2031, with a CAGR of 10.9% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2891

A biologic therapy is designated as a biosimilar when it demonstrates high similarity to an FDA-approved reference product used in the treatment of psoriasis. Psoriasis is a chronic autoimmune skin disorder marked by rapid skin cell proliferation, inflammation, and scaling. Following the expiration of patents on originator biologics, biosimilars are developed to adhere to stringent regulatory standards concerning safety, efficacy, and quality.

The global psoriasis biosimilars market is experiencing notable growth, primarily driven by the increasing prevalence of psoriasis and the growing demand for cost-effective therapeutic alternatives. Additionally, heightened awareness among healthcare professionals and patients regarding the clinical effectiveness and affordability of biosimilars is significantly contributing to their broader adoption and market expansion.

List of Prominent Players in the Psoriasis Biosimilars Market:
• Merck KGaA
• Coherus BioSciences
• Gyros Protein Technologies AB
• Fresenius Kabi
• Viatris
• Amgen Inc
• Samsung Bioepis Co., Ltd.
• Hoffmann-La Roche Ltd
• Celltrion
• Pfizer Inc.
• Samsung Bioepis
• Sandoz
• Novartis International AG
• Reddy's Laboratories
• GenScript

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The escalating costs of healthcare are prompting the adoption of biosimilars as cost-effective alternatives to originator biologics, offering comparable therapeutic efficacy at reduced prices. This shift has proven particularly beneficial for psoriasis patients, as biosimilars have shown effectiveness in symptom management and quality-of-life improvement. Payers and healthcare providers are increasingly inclined toward these more affordable solutions. Moreover, growing efforts to enhance healthcare accessibility in developing economies are further boosting demand. Government-backed initiatives promoting the use of biosimilars, especially in regions with a high prevalence of psoriasis, are accelerating market penetration. Additionally, the rising number of biosimilar approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is reinforcing market growth.

Challenges:
One of the key challenges facing the psoriasis biosimilars market is regulatory uncertainty associated with product development, approval, and commercialization. Inconsistencies in regulatory frameworks, evolving guidelines, and complexities in proving biosimilarity and interchangeability present significant hurdles. These factors create an unpredictable environment that can delay product launches and limit patient access to cost-effective therapies, thereby hindering the market's full potential.

Regional Trends:
North America is projected to maintain a dominant position in the psoriasis biosimilars market, supported by its advanced biotechnology infrastructure and leadership in pharmaceutical innovation. Concurrently, the Asia-Pacific region is emerging as a high-growth area, driven by increased investment in biopharmaceutical R&D and the adoption of cutting-edge technologies for biosimilar development. The region's substantial psoriasis burden is contributing to rising demand for effective and affordable treatments, positioning biosimilars as essential components in the management of chronic dermatological conditions.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2891

Recent Developments:
• In July 2023, Coherus introduced YUSIMRYTM, a biosimilar of Humira®, priced at $995 per carton in the United States. YUSIMRY, sanctioned by the United States Food and Drug Administration (FDA) in 2021, is a tumour necrosis factor (TNF) inhibitor indicated for alleviating the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Segmentation of Psoriasis Biosimilars Market-
By Drug Class-
• TNF-alpha inhibitors
o Infliximab
o Etanercept
o Adalimumab
• Other biosimilars
By Route of Administration-
• Subcutaneous
• Intravenous
• Oral
• Topical
By Indication-
• Plaque psoriasis
• Psoriatic arthritis
• Other types
By Distribution Channel-
• Hospital pharmacies
• Retail pharmacy chains
• Online pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/psoriasis-biosimilars-market/2891

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.